Instil Bio, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
TIL$6.35-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $669 | $5,371 |
| General and administrative | 5,349 | 9,109 |
| Restructuring and impairment charges | 992 | 16,082 |
| Total operating expenses | 7,010 | 30,562 |
| Loss from operations | (7,010) | (30,562) |
| Interest income | 678 | 1,175 |
| Interest expense | (1,552) | (1,098) |
| Other rental income | 2,242 | 2,242 |
| Gain on contract termination | 1,620 | — |
| Other (expense) income, net | (182) | 43 |
| Net loss | (4,204) | (28,200) |
| Other comprehensive loss: | ||
| Foreign currency translation | 131 | (159) |
| Unrealized loss on available-for-sale securities, net | (80) | (64) |
| Net comprehensive loss | $(4,153) | $(28,423) |
| Net loss per share, basic and diluted | $(0.62) | $(4.32) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 6,781,976 | 6,532,658 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.